TrialNature communications2026

Nivolumab plus ipilimumab for chemotherapy-refractory metastatic castration-resistant prostate cancer: results from the randomized portion of the phase 2 CheckMate 650 trial.

Padmanee Sharma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.